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Sex-linked immunodeficiency with thrombocyto-
penia and eczema, described by Wiskott [1] and 
Aldrich et al [2], is a devastating disease that has 
posed a fascinating enigma from both hematologic 
and immunologic points of view. Affected boys 
usually die in early childhood from infections, 
hemorrhage, or malignancies, and severe allergic 
reactions to environmental antigens add to their 
misery during life [3]. This immunologic paradox 
of hypersensitivity on the one hand and immuno-
deficiency on the other is but one of the puzzling 
features of this complex disease process. My pur-
pose here, after a brief review of some of the char-
acteristics of this disease, a possibly-related ani-
mal model, and a new theoretical model of B-cell 
differentiation, is to propose that the primary de-
fect of the immune system in the Wiskott-Aldrich 
syndrome (WAS) may lie in the triggering mecha-
nism for the IgM - IgD subline of B cells. 
PLATELET AB NORMALITY IN WISKOTT- ALDRI CH 
SYNDROME 
Thrombocytopenia probably occurs as a direct 
consequence of the primary genetic defect since it 
is often found immediately after birth. Uncon-
trolled bleeding is the cause of death in approxi-
mately 25 % of WAS patients. Platelet infusion 
studies in affected boys have revealed that the 
survival of homologous platelets is normal [4,5] but 
the survival of autologous platelets is markedly 
shortened [6 ,7]. This fact , and the usually normal 
numbers of megakaryocytes , suggest that the 
shortage of platelets is due to excessive destruction 
of abnormal platelets . This conclusion is further 
supported by the demonstration of increased phag-
ocytosis of platelets and both morphologic and 
chemical evidence of abnormal platelets in WAS 
patients [7 ,8]. Their platelets are smaller than 
normal, often display unusual variations in shape, 
and have reduced numbers of mitochondria and 
a-granules. Although platelets in WAS patients 
are intrinsically capable of phagocytosis, aggrega-
tion, and degranulation , they are relatively unre-
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sponsive to a variety of aggregating agents , such as 
adenosine diphosphate (ADP) , collagen , epineph-
rine , and polystyrene latex particles , perhaps 
because of a functional deficit of a physiologic 
stimulator of the citric acid cycle. 
IMM UN OLOGIC AB NORMALITIES 
The T-cell system appears to develop normally 
in WAS patients as evidenced by morphologic 
appraisal of the thymus , the presence of circulating 
T-Iymphocytes that respond to mitogens with 
normal proliferation , lymphokine production and 
killer activity, initial population of thymus-
dependent areas in lymph nodes , ability to respond 
in many cases to " thymus-dependent" antigens , 
and apparent integrity of cell-mediated immunity 
in some patients studied early in life [9-13]. 
However , with time there is a progressive attrition 
of T -cells in peripheral lymphoid tissues and of 
T-cell functions , often leading to a profound com-
promise in cell-mediated immunity. Reduced re-
sponses of patients ' lymphocytes when cultured 
with antigens and allogeneic lymphocytes and 
cutaneous anergy are associated with development 
of extreme susceptibility to infections with viruses , 
fungi , and Pneumo cystis cannu orgamsm 
[9-11 ,14,15 ]. 
The administration of transfer factor has been 
report ed in some patients to result in clinical 
improvement in terms of reduced numbers of 
infections , clearing or improvement in eczema, and 
reduced frequency of bleeding episodes without 
noticeable correction of the thrombocytopenia 
[16]. However , this evidence is not entirely con-
vincing since these clinical changes are inconsist-
ently seen , the course of the disease is highly 
variable , and no control studies have been done. 
Partial integrity of the B-cell system is indicated 
by the development of normal numbers of circulat-
ing B-Iymphocytes, an abundance of germinal 
centers and plasma cells in lymphoid tissues, 
production of all classes of immunoglobulins , and 
the ability to respond with antibody production to 
antigens that in rodents have been shown to 
require cooperative interactions between T- and 
B-cells [9,10,17 ,18]. On the other hand, a primary 
abnormality of the B-cell system is suggested by 
the rather consistent inability of WAS patients to 
produce IgM antibodies in response to stimulation 
by "thymus-independent" polysaccharide anti-
gens such as pneumococcal polysaccharides, endo-
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toxin, Forssman antigen, Vi antigen of Escherichia 
coli, and polysaccharide determinants of strep-
tococcal organisms [9,10,17 ,19]. This abnormality 
could account in part for the frequent occurrence of 
relatively low serum levels of IgM, although hyper-
catabolism of all major immunoglobulin classes 
has also been demonstrated [20]. Moreover, these 
patients also are unusually vulnerable to infections 
with bacterial agents, (pneumococci , a variety of 
gram-negative organisms, and staphylococci) in 
the absence of demonstrable defects in phagocytic 
cells and in the complement system [10 ,17,21]. 
Allergic manifestations , including eczema, 
asthma, urticarial reactions to foods, and diarrhea, 
are very com mon in WAS . Not surprisingly, IgE 
levels have been observed to be very high in some 
affected individuals but not in all [20,22]. 
MALIG NA:'-JCIES 
The occurrence of malignant neoplasms in more 
than 30 individuals with WAS has been reported to 
the Immunodeficiency-Cancer Registry (23; J. H. 
Kersey, personal communication). 1Vlost of these 
malignancies have been diagnosed after death , 
sometimes as incidental morphologic findings. The 
vast majority have been lymphoreticular malig-
nancies. So far , surface markers have not been 
used to determine the cell lineage or to gain 
evidence for a monoclonal process. Monoclonal IgG 
paraproteins have been seen on several occasions 
but have often been transient and not associated 
with lymphoreticular malignancy [24-26]. Mye-
logenous leukemia has been seen in a few patients 
with WAS, and multiple leiomyosarcomas 
occurred in one affected child. The overall inci-
dence of associated malignancies, estimated to be 
approximately 8%, is difficult to determine with 
precision, partly because of the difficulty in dis-
criminating between reticuloendothelial hyper-
plasia , a common occurrence in WAS, and malig-
nant reticuloendotheliosis. 
The recent occurrence of malignancies in 5 WAS 
patients receiving transfer factor , one of which was 
the first report of a disseminated cutaneous lym-
phoma [27], has raised further doubt about the 
relative value of this form of therapy . 
X-LINKED B-LYMPHOCYTE DEFECT I:'-J CBA/ H N MI CE 
CBA/HN mice are a sub line of CBA mice with a 
profound inability to produce antibodies to thy-
mus-independent antigens such as pneumococcal 
polysaccharide, lipopolysaccharide, polyriboino-
sinic-polyribocytidylic acid and DNP-Iys-Fi'coll 
[28-30]. Although CBA/HN mice and F 1 males 
have a reduced number of immunoglobulin-bear-
ing lymphocytes, reduced serum IgM levels (R. 
Asofsky, personal communication) and impaired 
responses to B-Iymphocyte mitogens, their B-Iym-
phocytes are capable of almost normal function in 
an antibody response to thymus-dependent anti-
gens. The X-linked defect in this mutant strain of 
mice has been shown to be an intrinsic defect of 
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B-Iymphocytes [30]. Although not an exact animal 
model of WAS, the similarities between the X-
linked immunodeficiency in these mice and that of 
WAS patients suggest that elucidation of this 
mouse B-Iymphocyte abnormality could shed light 
on some of the immunologic impairments seen in 
WAS and other similar human immunodeficiency 
diseases. 
A MODEL OF B-CELL DIFFERENTIATIO N FEATURING 
TWO MAJOR SUBLI0JES OF B-CELLS 
Recently we have proposed a modified version of 
the original model of B-cell differentiation [31], 
which may help to elucidate some of the immuno-
logic abnormalities in WAS and the related 
immunodeficiency in CBA/HN mice. Briefly, the 
model holds that during development B.u cells can 
differentiate along one of two pathways . Cells of 
one subline acquire IgD receptors in addition to 
IgM receptors. Having two effective receptors on 
their surface, these cells may be easily triggered by 
antigens to differentiate into mature IgM-secreting 
plasma cells. In humans a few cells of this subline , 
after losing the capacity of IgM synthesis, may 
proceed to become IgD-secreting cells. With T-cell 
help, IgM- IgD cells may be driven even more 
efficiently to IgM-plasma cell differentiation at the 
expense of memory-cell proliferation and with a 
loss in the capacity to increase the affinity of 
antibodies produced during an immune response . 
It is proposed that cells of the other B subline 
never express surface IgD but instead during their 
development switch directly to expression of IgG , 
and that subsequent progeny switch to IgA synthe-
sis as proposed in our original model [32]. Perhaps 
due to stability of mRNA for immunoglobulin , 
some cells may continue for a time to express the 
first class of immunoglobulin even after the genetic 
switch from one immunoglobulin class to another. 
Thus some carry-over might be expected, and 
these transitions reflected by the occurrence of 
cells with the combinations of IgM + IgG and IgG 
+ IgA on their surface or surface and cytoplasm. 
The need for T-cell help in the antigen-induced 
differentiation of IgG- and IgA-secreting plasma 
cells may reflect the relative ineffectiveness of the 
antibody receptors on cells of this subline. On the 
other hand , a reduced stimulus received by B), and 
BO' cells could favor memory-cell production and 
have the advantages of an efficient system for 
selecting in subsequent antigen responses those 
memory cells with surface antibodies of the highest 
affinities. 
This model will be discussed more fully else-
where but some of the observations which led us to 
this hypothesis are: In mice and humans IgM 
expression precedes IgD, IgG, and IgA expression 
[33;34; our unpublished observations], the simul-
taneous expression on the surface or surface + 
cytoplasm of two immunoglobulin classes by nor-
mal and malignant B-cell clones include the com-
binations of IgM + IgD, IgM + IgG, and IgG + 
IgA, but the combinations of IgD + IgG and IgD + 
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IgA have yet to be documented convincingly; 
several immunodeficiency diseases, including 
WAS and CAB/HN mice, can be more easily 
explained using this model; and in a pilot experi-
ment, antibodies to 0 chains partially inhibited the 
pokeweed-mitogen induction of IgM- but not IgG-
plasma cells (J. F. Kearney, A. R. Lawton, and M. 
D. Cooper, unpublished observation). 
In contrast to the model of B-cell differentiation 
recently proposed by Vitetta and Uhr [35], our 
model predicts that cells selected for the presence 
of surface IgD will only be inducible for IgM- and 
IgD-plasma cell differentiation, whereas a B-cell 
population depleted of IgD -+ cells should not be 
depleted of the precursors of IgG- and IgA-plasma 
cells. These and other experiments suggested by 
this hypothetical model are being done. 
CONCLUSIONS AND SPECULATIO ?>JS 
The primary immunologic defect in WAS may 
involve defective triggering of the IgM-IgD subline 
of B-cells as the basis for the severe impairment in 
antibody responsiveness to thymus-independent 
antigens and its clinical consequences (discussed 
in [10]). The defect could be one of faulty synthe-
sis of IgD-surface receptors . In regard to this pos-
sibility, it is notable that the lymphocyte-surface 
ratio ofIgD/lgM is reduced in CBA/HN mice (W. E. 
Paul, personal communication). An alternate pos-
sibility is that the density of surface IgD, because 
of its unusual susceptibility to fragmentation by 
proteolytic enzymes [36] could be secondarily re-
duced in concentration on the B-Iymphocyte sur-
face . It is conceivable that this phenomenon could 
be achieved by the same undefined process that 
causes the hypercatabolsim of serum immunoglob-
ulin in WAS patients [20]. The protein degrada-
tion process could extend to the lymphocyte sur-
face where it might have a profound effect on a 
variety of immune responses , but especially those 
of IgD-+ cells. Both of these possibilities should be 
examined not only in WAS patients but in other 
immunodeficient patients who have selectively 
impaired synthesis of IgM. 
Note Added in Proof 
Two boys with Wiskott-Aldrich syndrome have 
been found to have normal numbers of B-Ivm-
phocytes bearing surf~ce IgD, once again illustrat-
ing the short life span of most hypotheses. In other 
experiments, we have shown that surface IgD is 
secondarily expressed on B-lymphocytes bearing 
IgM, IgG, and IgA [37]. These results perhaps il-
lustrate that the main benefit of an hypothesis 
comes from insight provided when it is proved 
wrong. 
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DISCUSSION 
Millikan: The literature describes considerable 
phenotypic variation in the syndrome with many forme 
frustes including some primary platelet abnormalities 
alone . Do you interpret these as all part of the same 
syndrome or several similar diseases? 
Cooper: There is a wide variation in the clinical 
course of WAS patients, and there are a number of 
related X-linked thrombocytopenic syndromes with dif-
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ferin g phenotypic patterns, e.g. , thrombocytopenia and 
eczema without immunologic manifestations. I am 
unsure what this suggests about the nature of the basic 
genetic defect(s). 
Kantor: Why are Wiscott-Aldrich patients subject 
to a "consumptive immunopathy" or "immunologic attri-
tion"? The deficiency of responses to polysaccharide 
antigens does not explain this course, or does it? 
Cooper: The progressive depletion of lymphocytes , 
particularly T -cells, in the tissues of WAS patients , the 
reticuloendothelial hyperplasia , and the progressive 
immunodeficiency could be consequent to the damage 
wrought by endotoxin unchecked by antibody . 
Claman: What are the levels of immunoglobulin-
bearing cells of different classes in WAS? Antibodies to 
blood group substances deliberately used for immuniza-
tion are IgG , while natural isohemagglutinins are IgM. 
Why do these children not get these antibodies according 
to your model? 
Cooper: The proportion and class distribution of 
circulating B-Iym phocytes have been normal in around 
13 of the 17 WAS patients examined, and intermediate 
levels of circulating B-Iymphocytes were seen in the rest. 
Examination of lymphocyte surface IgD unfortunately 
has not yet been reported . The antibody response of WAS 
patients to immunization with soluble A and B sub-
stances or with human erythrocytes usually is transient 
at best. The immunoglobulin class of the antibodies 
produced has not been examined to my knowledge . 
Levis: Would you comment on IgE in your model of 
B-cell different iation? 
Cooper: The thymus dependency of IgE-antibody 
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responses leads me to think that IgE expression is by 
B-cells belonging to the thymus-dependent subline, pos-
tulated in our model; but I have no good idea about where 
IgE expression occurs in the switch sequence . 
Agnello: Do these children have malabsorption? 
The reason I ask is we have been studying a patient with 
IgA deficiency who has antibodies to bovine products and 
a malabsorption syndrome. 
Cooper: Malabsorption is not a common feature of 
W AS, although it might exist in some of the patients with 
chronic diarrhea , many of whom have apparent allergies 
to foods. 
Spitler: You mentioned that patients with the 
Wiskott-Aldrich syndrome may develop isohemag-
glutinins late in life. Would this not oppose the theory 
that the immune response is deteriorating with advanc-
ing age in these patients? 
Cooper: It is possible that the isohemagglutinins 
made relatively late in life by WAS patients reflect 
integrity of thymus-dependent responses of their B-cells . 
It might be interest ing to know the class of antibodies. 
Turk: I noticed in your slide of a depleted lymph 
node that there was depletion of the center of germinal 
centers with an onion-skin appearance of the background 
reticulum cells, as well as the depletion of paracortical 
areas. In this slide the marginal cuff of small lymphocytes 
appeared not to be affected. Do you ever get depletion of 
these B-cells as well? 
Cooper: Yes, the " hyalinization" changes in germi-
nal centers have been seen repeatedly in boys with WAS. 
They may even lose follicular lymphoid structure 
altogether. 
